Search Results

CalciMedica Inc. announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, 2024, according to preliminary lists of additions posted on Friday, May 24, 2024.

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC) today announced positive topline data from CARPO, the Company’s randomized, double-blind, placebo-controlled Phase 2b trial evaluating Auxora™ for the treatment of acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the first quarter ended March 31, 2024.

CalciMedica Inc. announced the acceptance of an abstract for poster presentation by a collaborator from Cedars-Sinai Medical Center at the upcoming Digestive Disease Week 2024 being held May 18-21 in Washington, DC and virtually.

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC) today announced that it will host a conference call on Thursday, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT to discuss topline data from the Company’s Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2023.

CalciMedica Inc. today announced that the last patient has been enrolled in its Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP).

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC) today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 10:40am – 11:10am ET.

CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC) today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Company’s lead product candidate, Auxora™

CalciMedica, Inc. announced that it has entered into a securities purchase agreement with new and existing investors to raise up to approximately $55 million in gross proceeds that includes initial upfront funding of $20.4 million and up to an additional approximately $34.2 million upon exercise of accompanying warrants.